MASCC Neutropenia, Infection & Myelosuppression Study Group

Leadership

Chair: Bernardo Rapoport, MD - South Africa
Vice-Chair: TBD

For more information or to contact the Study Group Leaders, please send an email to [email protected].

Past Workshops

• How Adherence to Guidelines Increases the Cost-Effectiveness of Supportive Care Interventions. MASCC/ISOO Annual Meeting, Washington, DC, 2017.
• Supportive Care for Patients Undergoing Immunotherapy. MASCC/ISOO Annual Meeting, Adelaide, Australia, 2016.
• Anemia in Cancer MASCC/ISOO Annual Meeting, Copenhagen, 2015
• Beware of Infections in Both Adults and Children. MASCC/ISOO Annual Meeting, Miami, 2014
• Emerging Drug Resistance in Febrile Neutropenia Management: A Global Perspective. MASCC/ISOO Annual Meeting, Berlin, 2013

Research Highlights

Identifying Patients at Low Risk for FN Complications: Development and Validation of the MASCC Risk Index Score
Febrile neutropenia (FN) is a life-threatening complication of cancer chemotherapy and is considered a medical emergency. The classic treatment strategy has been broad-spectrum antibiotics administered intravenously in a hospital setting, and most patients respond promptly with no complications. For more than 20 years, Jean Klastersky and colleagues have worked on the development and testing of a reliable tool for identifying patients at low risk for complications of FN. The resulting MASCC Risk Index Score makes it possible to identify patients who can safely be treated at home. This work began with a 1994 survey to identify independent predictive factors that could be assessed at fever onset in adult febrile neutropenic cancer patients being treated with chemotherapy. The resulting Risk Index Score has now seen more than 10 years of use and has proven to be a reliable and valuable tool to identify low risk patients. Read More >>

Clinical App

Calculate by QxMD - (Free) Calculate the MASCC Febrile Neutropenia score in addition to included tools which are useful in clinical practice and serve to impact diagnosis, treatment or determining prognosis.

 MASCC-Endorsed Practice Guidelines

International Pediatric Fever and Neutropenia Guideline  From The Hospital for Sick Children (SickKids.ca)
Fever and neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. The Study Group convened a panel of pediatric cancer and infectious diseases experts to develop an evidence-based guideline for the empiric management of pediatric FN. This guideline focuses on children and adolescents with cancer, or who are undergoing hematopoietic stem cell transplantation, and who have FN. The guideline is designed for healthcare professionals who care for these patients. Implementation requires adaptation to the local context and consideration of organizational barriers, such as the availability of a local infrastructure, to support different models of care.

Recent Member Publications

Recent Study Group member publications related to neutropenia, infection, and myelosuppression in patients with cancer.

Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Leslie Johnson